Unnamed: 0,title,date,stock,sentiment
836996.0,MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma,2020-04-21 06:14:00-04:00,MNOV,neutral
836997.0,78 Biggest Movers From Yesterday,2020-04-15 04:45:00-04:00,MNOV,neutral
836998.0,55 Stocks Moving In Tuesday's Mid-Day Session,2020-04-14 12:52:00-04:00,MNOV,neutral
836999.0,86 Biggest Movers From Yesterday,2020-04-14 05:19:00-04:00,MNOV,negative
837000.0,63 Stocks Moving In Monday's Mid-Day Session,2020-04-13 12:35:00-04:00,MNOV,neutral
837001.0,100 Biggest Movers From Thursday,2020-04-13 05:18:00-04:00,MNOV,neutral
837002.0,75 Stocks Moving In Thursday's Mid-Day Session,2020-04-09 13:02:00-04:00,MNOV,neutral
837003.0,86 Biggest Movers From Yesterday,2020-04-09 05:43:00-04:00,MNOV,negative
837004.0,65 Stocks Moving In Wednesday's Mid-Day Session,2020-04-08 12:35:00-04:00,MNOV,neutral
837005.0,MediciNova shares are trading higher after the company announced that it plans to initiate a clinical trial of MN-166 for coronavirus acute respiratory distress syndrome.,2020-04-08 08:53:00-04:00,MNOV,negative
837006.0,"The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO",2020-04-08 07:53:00-04:00,MNOV,neutral
837007.0,MediciNova Announces Plans To Initiate Clinical Trial Of MN-166 (ibudilast) For COVID-19 (Coronavirus) Acute Respiratory Distress Syndrome,2020-04-08 06:08:00-04:00,MNOV,negative
837008.0,144 Biggest Movers From Friday,2020-03-16 05:03:00-04:00,MNOV,neutral
837009.0,"B. Riley FBR Maintains Buy on MediciNova, Lowers Price Target to $11",2020-03-13 07:45:00-04:00,MNOV,negative
837010.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,MNOV,negative
837012.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,MNOV,negative
837013.0,Stocks That Hit 52-Week Lows On Wednesday,2020-03-11 11:41:00-04:00,MNOV,negative
837014.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,MNOV,positive
837015.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,MNOV,negative
837016.0,MediciNova Announces Plans to Develop MN-166 (ibudilast) for Severe Pneumonia and Acute Respiratory Distress Syndrome (ARDS),2020-03-09 19:13:00-04:00,MNOV,negative
837017.0,Stocks That Hit 52-Week Lows On Friday,2020-03-06 11:22:00-05:00,MNOV,negative
837018.0,Stocks That Hit 52-Week Lows On Friday,2020-02-28 10:16:00-05:00,MNOV,negative
837019.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,MNOV,neutral
837020.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,MNOV,negative
837021.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,MNOV,negative
837022.0,Stocks That Hit 52-Week Lows On Tuesday,2020-02-25 10:22:00-05:00,MNOV,negative
837023.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,MNOV,negative
837024.0,94 Biggest Movers From Friday,2020-02-24 04:53:00-05:00,MNOV,neutral
837025.0,68 Stocks Moving In Friday's Mid-Day Session,2020-02-21 12:29:00-05:00,MNOV,neutral
837026.0,Stocks That Hit 52-Week Lows On Friday,2020-02-21 10:56:00-05:00,MNOV,negative
837027.0,"The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion",2020-02-21 07:46:00-05:00,MNOV,negative
837028.0,Medicinova Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For Treatment Of Advanced NASH In Japan -,2020-02-17 18:37:00-05:00,MNOV,positive
837029.0,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",2020-02-07 07:32:00-05:00,MNOV,negative
837030.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-06 10:53:00-05:00,MNOV,negative
837031.0,Stocks That Hit 52-Week Lows On Friday,2020-01-31 11:00:00-05:00,MNOV,negative
837032.0,"The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO",2020-01-31 09:09:00-05:00,MNOV,negative
837033.0,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance",2020-01-30 09:26:00-05:00,MNOV,positive
837034.0,"The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics",2020-01-28 07:12:00-05:00,MNOV,positive
837035.0,MediciNova Receives Notice of Intention To Grant For New Patent Covering MN-001 For Treatment Of Idiopathic Pulmonary Fibrosis In Europe,2020-01-27 18:00:00-05:00,MNOV,positive
837036.0,Stocks That Hit 52-Week Lows On Monday,2020-01-27 10:42:00-05:00,MNOV,negative
837037.0,Stocks That Hit 52-Week Lows On Friday,2019-12-27 11:40:00-05:00,MNOV,negative
837038.0,"The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping",2019-12-27 07:59:00-05:00,MNOV,neutral
837039.0,"The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares",2019-12-26 07:55:00-05:00,MNOV,negative
837040.0,MediciNova Reports Added Analyses From Completed Trial Of MN-166 In ALS Presented At 30th Int'l. Symposium On ALS/MND,2019-12-04 18:01:00-05:00,MNOV,neutral
837041.0,MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada,2019-10-28 06:07:00-04:00,MNOV,neutral
837042.0,51 Biggest Movers From Friday,2019-10-28 05:27:00-04:00,MNOV,neutral
837043.0,MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in Japan,2019-10-23 06:05:00-04:00,MNOV,neutral
837044.0,46 Biggest Movers From Friday,2019-10-21 05:37:00-04:00,MNOV,neutral
837045.0,MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in Japan,2019-10-08 04:47:00-04:00,MNOV,neutral
837046.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-02 09:07:00-04:00,MNOV,neutral
837047.0,MediciNova Announces MN-001 Research Collaboration with the National Cerebral and Cardiovascular Disease Research Center in Japan,2019-07-31 03:59:00-04:00,MNOV,neutral
837048.0,"MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 30th International Symposium on ALS/MND in Perth, Australia",2019-07-30 03:56:00-04:00,MNOV,positive
837049.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-07-26 10:09:00-04:00,MNOV,neutral
837050.0,40 Biggest Movers From Friday,2019-07-15 05:47:00-04:00,MNOV,neutral
837051.0,36 Stocks Moving In Friday's Mid-Day Session,2019-07-12 12:38:00-04:00,MNOV,neutral
837052.0,MediciNova shares are trading higher after the company announced its Phase 3 clinical trial plan for MN-166 in progressive MS.,2019-07-12 08:16:00-04:00,MNOV,positive
837053.0,28 Stocks Moving In Friday's Pre-Market Session,2019-07-12 08:15:00-04:00,MNOV,neutral
837054.0,MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS,2019-07-12 04:12:00-04:00,MNOV,neutral
837055.0,64 Biggest Movers From Friday,2019-06-03 06:12:00-04:00,MNOV,neutral
837056.0,Shares of many healthcare companies are trading lower following a tweet from President Trump late Thursday stating the US will impose a 5 percent tariff on goods from Mexico.,2019-05-31 10:25:00-04:00,MNOV,negative
837057.0,52 Biggest Movers From Yesterday,2019-05-21 05:05:00-04:00,MNOV,neutral
837058.0,36 Stocks Moving In Monday's Mid-Day Session,2019-05-20 12:32:00-04:00,MNOV,neutral
837059.0,"The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering",2019-05-17 08:03:00-04:00,MNOV,neutral
837060.0,"MediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the Official Launch of Myelopathy.org in London, United Kingdom",2019-05-08 03:49:00-04:00,MNOV,positive
837061.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs",2019-05-04 16:56:00-04:00,MNOV,neutral
837062.0,"The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova",2019-04-24 08:09:00-04:00,MNOV,neutral
837063.0,MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma,2019-04-24 04:02:00-04:00,MNOV,neutral
837064.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,MNOV,positive
837065.0,45 Biggest Movers From Yesterday,2019-04-23 05:59:00-04:00,MNOV,neutral
837066.0,34 Stocks Moving In Monday's Mid-Day Session,2019-04-22 12:17:00-04:00,MNOV,neutral
837067.0,"The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives",2019-04-16 08:10:00-04:00,MNOV,neutral
837068.0,MediciNova Announces FDA Determines Co Can Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS,2019-04-16 04:07:00-04:00,MNOV,neutral
837069.0,46 Biggest Movers From Yesterday,2019-04-11 05:09:00-04:00,MNOV,neutral
837070.0,33 Stocks Moving In Wednesday's Mid-Day Session,2019-04-10 13:17:00-04:00,MNOV,neutral
837071.0,"MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in China",2019-04-03 19:05:00-04:00,MNOV,neutral
837072.0,54 Biggest Movers From Yesterday,2019-04-03 05:42:00-04:00,MNOV,neutral
837073.0,51 Stocks Moving In Tuesday's Mid-Day Session,2019-04-02 12:27:00-04:00,MNOV,neutral
837074.0,MediciNova shares are trading higher after the company announced positive results of a subgroup analysis from its SPRINT-MS Phase 2b trial of MN-166 in progressive MS.,2019-04-02 10:38:00-04:00,MNOV,positive
837075.0,MediciNova Announces Results of Subgroup Analysis from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS,2019-04-02 05:51:00-04:00,MNOV,neutral
837076.0,"B. Riley FBR Assumes MediciNova at Buy, Announces Price Target $22",2019-03-25 07:23:00-04:00,MNOV,neutral
837077.0,"MediciNova Announces MN-001 Research Collaboration with Jikei University School of Medicine in Tokyo, Japan",2019-03-06 04:08:00-05:00,MNOV,neutral
837078.0,71 Biggest Movers From Yesterday,2019-02-20 04:49:00-05:00,MNOV,neutral
837079.0,54 Stocks Moving In Tuesday's Mid-Day Session,2019-02-19 13:01:00-05:00,MNOV,neutral
837080.0,61 Biggest Movers From Friday,2019-02-19 05:14:00-05:00,MNOV,neutral
837081.0,52 Stocks Moving In Friday's Mid-Day Session,2019-02-15 12:35:00-05:00,MNOV,neutral
837082.0,"The Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal",2019-02-15 07:39:00-05:00,MNOV,positive
837083.0,71 Biggest Movers From Yesterday,2019-02-15 04:59:00-05:00,MNOV,neutral
837084.0,52 Stocks Moving In Thursday's Mid-Day Session,2019-02-14 12:27:00-05:00,MNOV,neutral
837085.0,30 Stocks Moving In Thursday's Pre-Market Session,2019-02-14 08:07:00-05:00,MNOV,neutral
837086.0,MediciNova On Monday Announced Notice Of Allowance For New Patent Covering Combination Of MN-166 And Riluzole For Amyotrophic Lateral Sclerosis And other Neurodegenerative Diseases,2019-01-22 08:56:00-05:00,MNOV,neutral
837087.0,"The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study",2019-01-09 07:39:00-05:00,MNOV,negative
837088.0,MediciNova Reports Initiation Of Enrollment In MN-166 Trial For Glioblastoma,2019-01-08 18:20:00-05:00,MNOV,neutral
837089.0,MediciNova Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For Treatment Of Fibrosis In Japan,2019-01-07 18:01:00-05:00,MNOV,neutral
837090.0,MediciNova Sees FY18 EPS (0.44) vs $(0.45) Estimate,2018-10-26 06:16:00-04:00,MNOV,neutral
837091.0,"The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker",2018-10-05 08:35:00-04:00,MNOV,positive
837092.0,MediciNova Announces FDA Orphan Drug Designation to MN-166 for Glioblastoma,2018-10-05 04:27:00-04:00,MNOV,neutral
837093.0,"MediciNova Late Tuesday Reported FDA Feedback Regarding Phase 3 Plan For MN-166 (ibudilast) In ALS; FDA Said If A Single Trial Shows Statistically Significant Benefit, Additional Trial May Not Be Necessary",2018-09-26 07:59:00-04:00,MNOV,positive
837094.0,MediciNova Announces Publication Of Results Of SPRINT-MS Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS In New England Journal Of Medicine,2018-08-29 17:03:00-04:00,MNOV,neutral
837095.0,44 Biggest Movers From Friday,2018-08-27 04:34:00-04:00,MNOV,neutral
837096.0,40 Stocks Moving In Friday's Mid-Day Session,2018-08-24 12:47:00-04:00,MNOV,neutral
837097.0,National Institute on Alcohol Abuse and Alcoholism Awards R01 Research Grant to UCLA for Phase 2b Clinical Trial of MediciNova's MN-166 (ibudilast) in Alcohol Use Disorder,2018-08-21 04:04:00-04:00,MNOV,negative
837098.0,MediciNova Late Monday Announced Initiation Of NIHR Grant-Funded Phase 2/3 Trial Of MN-166 (ibudilast) For Degenerative Cervical Myelopathy In Collaboration With University Of Cambridge,2018-08-07 09:05:00-04:00,MNOV,neutral
837099.0,"MediciNova Announces MN-166 ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK",2018-08-01 03:53:00-04:00,MNOV,positive
837100.0,MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial,2018-07-29 20:17:00-04:00,MNOV,neutral
837101.0,41 Biggest Movers From Yesterday,2018-07-11 04:38:00-04:00,MNOV,neutral
837102.0,32 Stocks Moving In Tuesday's Mid-Day Session,2018-07-10 12:20:00-04:00,MNOV,neutral
837103.0,Mid-Morning Market Update: Markets Open Higher; PepsiCo Beats Q2 Expectations,2018-07-10 10:15:00-04:00,MNOV,neutral
837104.0,MediciNova Late Monday Announced Clinical Data From Subgroup Analyses Of Completed Clinical Trial Of MN-166 (ibudilast) In ALS,2018-07-10 08:44:00-04:00,MNOV,neutral
837105.0,20 Stocks Moving In Tuesday's Pre-Market Session,2018-07-10 08:01:00-04:00,MNOV,neutral
837106.0,34 Biggest Movers From Friday,2018-07-09 04:25:00-04:00,MNOV,neutral
837107.0,32 Stocks Moving In Friday's Mid-Day Session,2018-07-06 12:38:00-04:00,MNOV,neutral
837108.0,Mid-Day Market Update: Crude Oil Up Over 1%; Black Box Shares Spike Higher,2018-07-06 12:12:00-04:00,MNOV,negative
837109.0,"Mid-Morning Market Update: Markets Mostly Higher; U.S. Adds 213,000 Jobs For June",2018-07-06 10:10:00-04:00,MNOV,neutral
837110.0,42 Biggest Movers From Yesterday,2018-07-06 04:18:00-04:00,MNOV,neutral
837111.0,30 Stocks Moving In Thursday's Mid-Day Session,2018-07-05 12:24:00-04:00,MNOV,neutral
837112.0,MediciNova Late Tuesday Received  Notice Of Allowance For New Patent Covering MN-001 For Treatment of Hypertriglyceridemia And Hypercholesterolemia In Japan,2018-06-20 08:46:00-04:00,MNOV,neutral
837113.0,MediciNova Late Wednesday Announced Opening Of Investigational New Drug Application For MN-166 (ibudilast) In Glioblastoma,2018-05-10 09:06:00-04:00,MNOV,neutral
837114.0,32 Stocks Moving In Thursday's Pre-Market Session,2018-05-10 08:08:00-04:00,MNOV,neutral
837115.0,MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 in Alcohol Use Disorder and Withdrawal,2018-05-08 03:43:00-04:00,MNOV,negative
837116.0,MediciNova Late Thursday Announced Additional Data From Completed Clinical Trial Of MN-166 (ibudilast) In ALS Presented At American Academy Of Neurology (AAN) 70th Annual Meeting,2018-04-27 09:11:00-04:00,MNOV,neutral
837117.0,"Benzinga's Daily Biotech Pulse: Intra-cellular Moves On Poster Presentation, Earnings Beats From Vertex, Exact Sciences",2018-04-27 07:25:00-04:00,MNOV,neutral
837118.0,"MediciNova Offers Data From SPRINT-MS Phase 2b Trial Of MN-166 In Progressive MS: For Primary Endpoint, Showed Statistically Significant 48% Reduction In Rate Of Progression, Secondary Endpoint Showed 80% Reduction",2018-04-24 06:36:00-04:00,MNOV,positive
837119.0,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",2018-04-20 14:00:00-04:00,MNOV,neutral
837120.0,40 Biggest Movers From Friday,2018-04-16 05:19:00-04:00,MNOV,neutral
837121.0,"MediciNoava Shares Sell Off Sharply From Premarket, Down ~18.5%; Co. Reported MN-001 Study Showed Significant Serum Triglyceride Reduction In Liver Disease Patients, Co. Will Discontinue Enrollment To Accelerate Further Development",2018-04-13 15:21:00-04:00,MNOV,positive
837122.0,30 Stocks Moving In Friday's Mid-Day Session,2018-04-13 12:17:00-04:00,MNOV,neutral
837123.0,Benzinga Pro's 5 Stocks To Watch Today,2018-04-13 08:30:00-04:00,MNOV,neutral
837124.0,28 Stocks Moving In Friday's Pre-Market Session,2018-04-13 08:12:00-04:00,MNOV,neutral
837125.0,"UPDATE: MediciNova Says Due To Fact Most Important Endpoint For MN-001 Study Was Achieved, Co. Will Discontinue Enrollment, Stop Study In Order To Accelerate Further Development",2018-04-13 06:34:00-04:00,MNOV,neutral
837126.0,"UPDATE: MediciNova Says After 8 Weeks Of Treatment With MN-001, Serum Triglyceride Level Reduced In 13 Out Of 14 Subjects",2018-04-13 06:33:00-04:00,MNOV,neutral
837127.0,MediciNova Reports Results From Interim Analysis Of Phase 2 Trial Of MN-001 In NASH / NAFLD: Showed 'reduces serum triglycerides significantly in NASH and NAFLD patients with hypertriglyceridemia after 8 weeks of treatment',2018-04-13 06:32:00-04:00,MNOV,neutral
837128.0,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",2018-04-06 12:55:00-04:00,MNOV,neutral
837129.0,41 Biggest Movers From Yesterday,2018-04-03 04:18:00-04:00,MNOV,neutral
837130.0,33 Stocks Moving In Monday's Mid-Day Session,2018-04-02 12:53:00-04:00,MNOV,neutral
837131.0,MediciNova Shares Up 20.2% After Co. On Sun. Announced Early Termination Of Phase 2 MN-001 Trial Based On Positive Results From Interim Analysis,2018-04-02 12:52:00-04:00,MNOV,positive
837132.0,"Benzinga Pro's Most-Searched Tickers For Mon., Apr. 2, 2018",2018-04-02 11:40:00-04:00,MNOV,neutral
837133.0,"'$MNOV experimental drug might reduce fat in blood, but a NASH cure? Not so fast' - Stat News' Adam F",2018-04-02 11:03:00-04:00,MNOV,neutral
837134.0,Benzinga Pro's 5 Stocks To Watch Today,2018-04-02 10:04:00-04:00,MNOV,neutral
837135.0,41 Biggest Movers From Thursday,2018-04-02 05:21:00-04:00,MNOV,neutral
837136.0,MediciNova Announces Phase 2 Trial of MN-001 in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis,2018-04-01 19:34:00-04:00,MNOV,positive
837137.0,Mid-Afternoon Market Update: NASDAQ Up 2%; Movado Shares Surge On Earnings Beat,2018-03-29 14:33:00-04:00,MNOV,positive
837138.0,MediciNova Shares Down 19.7% After Phase 2 Clinical Trial Of MN-166 Didn't Meet Primary Endpoint,2018-03-29 12:26:00-04:00,MNOV,positive
837139.0,36 Stocks Moving In Thursday's Mid-Day Session,2018-03-29 12:21:00-04:00,MNOV,neutral
837140.0,26 Stocks Moving In Thursday's Pre-Market Session,2018-03-29 08:22:00-04:00,MNOV,neutral
837141.0,MediciNova Reports Phase 2 Clinical Trial Of MN-166 Did Not Meet Primary Endpoint,2018-03-29 06:30:00-04:00,MNOV,neutral
837142.0,"B. Riley Initiates Coverage On MediciNova with Buy Rating, Announces $22.00 Price Target",2018-03-28 08:01:00-04:00,MNOV,neutral
837143.0,45 Biggest Movers From Yesterday,2018-03-14 04:55:00-04:00,MNOV,neutral
837144.0,35 Stocks Moving In Tuesday's Mid-Day Session,2018-03-13 12:28:00-04:00,MNOV,neutral
837145.0,MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at #AAN2018,2018-02-18 18:02:00-05:00,MNOV,neutral
837146.0,28 Stocks Moving In Friday's Pre-Market Session,2018-02-09 08:06:00-05:00,MNOV,neutral
837147.0,46 Biggest Movers From Yesterday,2018-02-09 04:36:00-05:00,MNOV,neutral
837148.0,45 Stocks Moving In Thursday's Mid-Day Session,2018-02-08 12:25:00-05:00,MNOV,neutral
837149.0,26 Stocks Moving In Thursday's Pre-Market Session,2018-02-08 08:03:00-05:00,MNOV,neutral
837150.0,MediciNova Prices ~4.4M Share Public Offering of Common Stock @$9.05/Share,2018-02-08 04:11:00-05:00,MNOV,positive
837151.0,MediciNova Announces an Offering,2018-02-07 16:01:00-05:00,MNOV,neutral
837152.0,40 Biggest Movers From Yesterday,2018-02-07 05:09:00-05:00,MNOV,neutral
837153.0,30 Stocks Moving In Tuesday's Mid-Day Session,2018-02-06 12:06:00-05:00,MNOV,neutral
837154.0,20 Stocks Moving In Tuesday's Pre-Market Session,2018-02-06 08:03:00-05:00,MNOV,neutral
837155.0,31 Stocks Moving In Monday's Mid-Day Session,2018-02-05 12:43:00-05:00,MNOV,neutral
837156.0,"MediciNova Shares Moving Lower Over Last Few Minutes, Traders Circulating A Negative Report From Art Doyle; Alleges Co. Is Hiding Important Data That Shows Its ibudilast Treatment Is 'Almost Certainly Inert'",2018-02-05 12:06:00-05:00,MNOV,negative
837157.0,Mid-Morning Market Update: Markets Open Lower; Bristol-Myers Profit Tops Expectations,2018-02-05 10:13:00-05:00,MNOV,positive
837158.0,28 Stocks Moving In Monday's Pre-Market Session,2018-02-05 08:07:00-05:00,MNOV,neutral
837159.0,MediciNova Reports MN-166 Showed 26% Reduction In Confirmed Disability Progression In SPRINT-MS Phase 2b Trial In Progressive MS,2018-02-01 18:00:00-05:00,MNOV,neutral
837160.0,MediciNova Reports Presentation Of SPRINT-MS Phase 2b Study Of MN-166 In Progressive MS At ACTRIMS Forum,2018-01-31 07:04:00-05:00,MNOV,neutral
837161.0,MediciNova Reports MN-166 ALS Abstract Accepted For Presentation At AAN Meeting,2018-01-30 18:00:00-05:00,MNOV,positive
837162.0,45 Biggest Movers From Friday,2018-01-29 04:17:00-05:00,MNOV,neutral
837163.0,MediciNova Announces MN-001 (tipelukast) NASH/NAFLD Phase 2 Trial Interim Results Selected for Presentation at #ILC2018,2018-01-28 18:04:00-05:00,MNOV,neutral
837164.0,"MediciNova Reports Top-Line Results From MN-166 ALS Trial: Primary Endpoint Of Safety, Tolerability Met, Efficacy Trends In Favor",2017-12-07 18:01:00-05:00,MNOV,positive
837165.0,"MediciNova Reports Collaboration With US Dept. Of Veterans Affair, Oregon Health & Science University To Evaluate MN-166 In Methamphetamine Use Disorder",2017-11-09 18:00:00-05:00,MNOV,negative
837166.0,30 Stocks Moving In Monday's Pre-Market Session,2017-10-30 08:05:00-04:00,MNOV,neutral
837167.0,MediciNova Gives Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166,2017-10-30 06:10:00-04:00,MNOV,neutral
837168.0,50 Biggest Movers From Friday,2017-10-30 05:13:00-04:00,MNOV,neutral
837169.0,45 Stocks Moving In Friday's Mid-Day Session,2017-10-27 12:32:00-04:00,MNOV,neutral
837170.0,32 Stocks Moving In Friday's Pre-Market Session,2017-10-27 08:04:00-04:00,MNOV,neutral
837171.0,30 Stocks Moving In Thursday's Pre-Market Session,2017-10-26 08:06:00-04:00,MNOV,neutral
837172.0,MediciNova Reports Top-Line Results From SPRINT-MS Phase 2b Trial Of MN-166 In Progressive MS: Achieved Both Primary Endpoints,2017-10-26 06:27:00-04:00,MNOV,neutral
837173.0,MediciNova Announces Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 in Progressive MS: Achieved Both Primary Endpoints including a Significant Reduction in Whole Brain Atrophy and Safety and Tolerability,2017-10-26 06:11:00-04:00,MNOV,positive
837174.0,The Week Ahead: Earnings Season Starts In Earnest,2017-10-23 09:00:00-04:00,MNOV,positive
837175.0,Mid-Morning Market Update: Markets Edge Lower; Costco Earnings Beat Expectations,2017-10-06 10:12:00-04:00,MNOV,negative
837176.0,20 Biggest Mid-Day Losers For Thursday,2017-10-05 12:52:00-04:00,MNOV,negative
837177.0,Mid-Day Market Update: Onvia Climbs On Acquisition News; Intellicheck Shares Plummet,2017-10-05 12:14:00-04:00,MNOV,positive
837178.0,Mid-Morning Market Update: Markets Open Higher; Constellation Brands Earnings Beat Views,2017-10-05 10:13:00-04:00,MNOV,neutral
837179.0,MediciNova Announces Completion of Phase 2 MN-166 Enrollment,2017-09-19 06:04:00-04:00,MNOV,neutral
837180.0,MediciNova Offers Results from Glioblastoma Animal Model Study at ASCO,2017-06-05 16:01:00-04:00,MNOV,neutral
837181.0,MediciNova to Offer off-floor Distribution of 800K Shares on Tokyo Stock Exchange from June 13 to June 15 -Reuters,2017-06-05 04:34:00-04:00,MNOV,positive
837182.0,18 Biggest Mid-Day Gainers For Wednesday,2017-04-26 12:28:00-04:00,MNOV,neutral
837183.0,Mid-Morning Market Update: Markets Edge Higher; Twitter Earnings Beat Views,2017-04-26 10:18:00-04:00,MNOV,neutral
837184.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-04-26 08:22:00-04:00,MNOV,neutral
837185.0,MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 Show Significantly Higher Survival Rate in ALS at AAN,2017-04-26 04:36:00-04:00,MNOV,neutral
837186.0,10 Biggest Mid-Day Losers For Wednesday,2017-04-12 13:57:00-04:00,MNOV,negative
837187.0,19 Stocks Moving In Wednesday's Pre-Market Session,2017-04-12 09:10:00-04:00,MNOV,neutral
837188.0,MediciNova Reports EC Has Granted Orphan Medicinal Product Designation for MN-166 for Amyotrophic Lateral Sclerosis,2016-12-20 18:01:00-05:00,MNOV,positive
837189.0,MediciNova Announces Phase 2b Trial of MN-166 in Progressive MS will Continue as Planned Following DSMB Review of Interim Efficacy Analysis,2016-12-19 06:04:00-05:00,MNOV,neutral
837190.0,MediciNova Announces Data From Clinical Trial,2016-12-09 06:01:00-05:00,MNOV,neutral
837191.0,"S-3 from Medicinova Shows Registration for Nearly ~870K Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants, via Selling Holders",2016-11-29 16:58:00-05:00,MNOV,positive
837192.0,MediciNova Sees FY2016 EPS $(0.31) Which May Not Compare $(0.08) Est,2016-10-26 06:11:00-04:00,MNOV,neutral
837193.0,NASH Sympathy Plays On Tobira Therapeutics Deal,2016-09-20 14:43:00-04:00,MNOV,positive
837194.0,Mid-Morning Market Update: Markets Open Higher; USG To Divest L&W Supply For $670M,2016-08-29 09:56:00-04:00,MNOV,neutral
837195.0,MediciNova Sees FY2016 EPS $(0.31) vs $(0.07) Est,2016-07-27 06:24:00-04:00,MNOV,neutral
837196.0,MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis,2016-07-24 19:01:00-04:00,MNOV,neutral
837197.0,MediciNova Reports Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 in Progressive MS,2016-07-13 06:30:00-04:00,MNOV,neutral
837198.0,Mid-Morning Market Update: Markets Edge Lower; Microsoft To Acquire LinkedIn For $26 Billion,2016-06-13 09:58:00-04:00,MNOV,negative
837199.0,MediciNova to Offer Off-floor Distribution of 800Kk Shares on Tokyo Stock Exchange between May 17 and May 19,2016-05-10 04:27:00-04:00,MNOV,positive
837200.0,MediciNova's Kessan Tanshin Reports FY16 Operating Loss $10.254M,2016-04-28 06:29:00-04:00,MNOV,negative
837201.0,Mid-Day Market Update: Knowles Rises On Upbeat Results; Sarepta Therapeutics Shares Decline,2016-04-26 12:01:00-04:00,MNOV,positive
837202.0,Mid-Morning Market Update: Markets Open Higher; Procter & Gamble Profit Tops Expectations,2016-04-26 10:13:00-04:00,MNOV,positive
837203.0,MediciNova Provides Interim MN-166 Update,2016-04-20 06:01:00-04:00,MNOV,neutral
837204.0,MediNova Sells Off to Low of $8.90 on Volume,2016-04-18 10:09:00-04:00,MNOV,negative
837205.0,10 Stocks Moving In Thursday's Pre-Market Session,2016-04-07 08:25:00-04:00,MNOV,neutral
837206.0,Mid-Afternoon Market Update: Dow Drops Over 50 Points; Edwards Lifesciences Shares Rise Following Positive Trial,2016-04-04 14:41:00-04:00,MNOV,positive
837207.0,Mid-Morning Market Update: Markets Mostly Flat; Alaska Air To Acquire Virgin America For $57/Share,2016-04-04 10:12:00-04:00,MNOV,neutral
837208.0,"The Market In 5 Minutes: Thursday, March 31, 2016",2016-03-31 11:32:00-04:00,MNOV,neutral
837209.0,10 Stocks Moving In Thursday's Pre-Market Session,2016-03-31 08:17:00-04:00,MNOV,neutral
837210.0,MediciNova Gains 6% Following Positive Mention In Medical Journal,2016-03-31 07:55:00-04:00,MNOV,positive
837211.0,MediciNova Announces Publication of Positive Findings from Completed Phase 1b Clinical Trial of MN-166  in Methamphetamine Dependence,2016-03-31 04:53:00-04:00,MNOV,positive
837212.0,MediciNova Receives Notice of Allowance for New Patent Covering MN-001 in China,2016-03-27 19:08:00-04:00,MNOV,neutral
837213.0,"MediciNova Announces Notice of Allowance for New Patent Covering MN-001, MN-002 for Treatment of Hypertriglyceridemia, Hypercholesterolemia, Hyperlipoproteinemia",2016-03-24 04:46:00-04:00,MNOV,neutral
837214.0,MediciNova Announces Receiving Fast Track Designation for MN-166,2016-03-22 06:11:00-04:00,MNOV,neutral
837215.0,Mid-Afternoon Market Update: Stratasys Rises On Upbeat Q4 Results; Ciena Shares Slide,2016-03-03 14:31:00-05:00,MNOV,positive
837216.0,Mid-Day Market Update: Stage Stores Drops On Earnings Miss; Tumi Holdings Shares Jump,2016-03-03 12:06:00-05:00,MNOV,positive
837217.0,Medicinova Halted on Circuit Breaker,2016-03-03 10:26:00-05:00,MNOV,neutral
837218.0,Medicinova Sells Off to Low of $5.96 on Volume; May be Attributed to Seeking Alpha Post,2016-03-03 10:24:00-05:00,MNOV,negative
837219.0,Stocks Hitting 52-Week Highs,2016-02-25 10:03:00-05:00,MNOV,neutral
837220.0,10 Stocks Moving In Thursday's Pre-Market Session,2016-02-25 08:17:00-05:00,MNOV,neutral
837221.0,10 Stocks Moving In Wednesday's Pre-Market Session,2016-02-03 08:24:00-05:00,MNOV,neutral
837222.0,"MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002, Treats Advanced NASH With Fibrosis",2016-01-27 18:00:00-05:00,MNOV,positive
837223.0,Mid-Day Market Update: Crude Oil Falls 5%; Tyco Shares Surge Following Johnson Controls Merger Agreement,2016-01-25 12:29:00-05:00,MNOV,positive
837224.0,Mid-Morning Market Update: Markets Open Lower; McDonald's Beats Q4 Estimates,2016-01-25 10:01:00-05:00,MNOV,negative
837225.0,FDA Grants Rare Pediatric Disease Designation to MediciNova's MN-166 for Treatment of Krabbe Disease,2016-01-18 18:14:00-05:00,MNOV,positive
837226.0,MediciNova Receives Notice of Allowance for New Patent Covering MN-029 di-hydrochloride in Europe,2016-01-13 18:02:00-05:00,MNOV,neutral
837227.0,MediciNova Reports Notice of Allowance for New Patent Covering MN-029 in Europe,2016-01-13 18:00:00-05:00,MNOV,neutral
837228.0,Benzinga's Top #PreMarket Gainers,2016-01-07 08:23:00-05:00,MNOV,positive
837229.0,FDA Grants Fast Track Designation for MediciNova's MN-166 for Treatment of ALS,2015-12-16 06:07:00-05:00,MNOV,positive
837230.0,MediciNova Receives Notice of Allowance for New Patent Covering MN-029 di-hydrochloride in China,2015-12-14 18:00:00-05:00,MNOV,neutral
837231.0,"MediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of MN-166 in ALS at 26th International Symposium on ALS/MND in Orlando, FL",2015-12-13 18:49:00-05:00,MNOV,positive
837232.0,"Early Global News: Final Draft Of Global Climate Change Deal, China's Retail Sales Up, Bridgestone To Acquire Pep Boys",2015-12-12 14:15:00-05:00,MNOV,neutral
837233.0,"UPDATE: MediciNova Says Ibudilast Did Not Impact Cue-, Stress-Induced Alcohol Craving, Increased Positive Mood",2015-12-09 17:36:00-05:00,MNOV,positive
837234.0,"MediciNova Reports Findings from Trial of MN-166 in AUD Reported at ACNP Meeting: Ibudilast Significantly Decreased Basal, Daily Alcohol Craving",2015-12-09 17:35:00-05:00,MNOV,neutral
837235.0,MediciNova Announces Presentation Regarding Clinical Trial of MN-166 in ALS at California ALS Pac10 and Research Network Meeting,2015-12-06 18:55:00-05:00,MNOV,neutral
837236.0,Medicinova Says FDA Has Granted Fast Track Designation,2015-11-19 06:03:00-05:00,MNOV,positive
837237.0,MediciNova Receives Notice of Allowance for New Patent Covering MN-221 (bedoradrine) for the Treatment of Irritable Bowel Syndrome in Japan,2015-11-10 18:01:00-05:00,MNOV,negative
837238.0,US Stock Futures Edge Higher Ahead Of Economic Data,2015-10-09 07:03:00-04:00,MNOV,neutral
837239.0,MediciNova to Initiate Clinical Trial of MN-001 (tipelukast) in IPF,2015-10-09 06:01:00-04:00,MNOV,neutral
837240.0,15 Stocks Moving In Friday's After-Hours Trading,2015-09-25 17:11:00-04:00,MNOV,neutral
837241.0,Morning Market Gainers,2015-09-10 09:43:00-04:00,MNOV,neutral
837242.0,Benzinga's Top #PreMarket Gainers,2015-09-10 08:13:00-04:00,MNOV,positive
837243.0,Medicinova Gets Fast Track Designation From FDA For MN-001,2015-09-10 06:00:00-04:00,MNOV,neutral
837244.0,MediciNova Announces First Advanced ALS Patient Using Non-Invasive Ventilation Support Enrolled in Phase 2 Clinical Trial of MN-166,2015-09-02 20:16:00-04:00,MNOV,positive
837245.0,Morning Market Losers,2015-08-19 09:52:00-04:00,MNOV,negative
837246.0,Benzinga's Top #PreMarket Losers,2015-08-19 08:22:00-04:00,MNOV,negative
837247.0,MediciNova Prices 5M Share Offering @$3.50/Share,2015-08-18 20:53:00-04:00,MNOV,positive
837248.0,"Tuesday's After-Hours Movers Led By Analog Devices, Canadian Solar And Weibo",2015-08-18 17:01:00-04:00,MNOV,neutral
837249.0,MediciNova Reports Proposed Public Offering Stock,2015-08-18 16:00:00-04:00,MNOV,neutral
837250.0,"Market Update: Monday's Mid-Day Movers, China's Stock Market Crash And More",2015-07-27 12:36:00-04:00,MNOV,negative
837251.0,Morning Market Gainers,2015-07-27 09:39:00-04:00,MNOV,neutral
837252.0,Benzinga's Top #PreMarket Gainers,2015-07-27 08:13:00-04:00,MNOV,positive
837253.0,MediciNova Reports FDA Approval of the Second Phase 2 Protocol for MN-001 in NASH Which Targets NASH Patients With Hypertriglyceridemia,2015-07-27 08:05:00-04:00,MNOV,positive
837254.0,MediciNova Gives Update On Development Plans For MN-001 In IPF,2015-07-21 08:03:00-04:00,MNOV,neutral
837255.0,MediciNova Presents of Interim Data from Clinical Trial of MN-166 in Alcohol Dependence at the 38th Annual RSA Scientific Meeting,2015-06-24 09:01:00-04:00,MNOV,neutral
837256.0,MediciNova Announces Randomization of 255 Subjects Completed in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS,2015-06-12 06:00:00-04:00,MNOV,neutral
837257.0,Morning Market Gainers,2015-06-03 09:41:00-04:00,MNOV,neutral
837258.0,MediciNova Reports FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Krabbe Disease,2015-06-03 08:01:00-04:00,MNOV,positive
837259.0,MediciNova Reports FDA Orphan Drug Designation for MN-166 for Krabbe Disease,2015-06-03 08:00:00-04:00,MNOV,neutral
837260.0,MediciNova Recieves FDA Designation For Ibudilast,2015-06-02 10:08:00-04:00,MNOV,neutral
837261.0,"Medicinova Expects FY EPS -$0.40, Est -$0.33",2015-05-12 06:30:00-04:00,MNOV,neutral
837262.0,Baseline Characteristics of 228 Subjects Enrolled in MediciNova's Phase 2b Trial of MN-166 in Progressive MS Presented at AAN,2015-04-23 19:34:00-04:00,MNOV,neutral
837263.0,MediciNova Announces Positive Interim Safety Data From Clinical Trial of MN-166 in ALS,2015-04-21 13:45:00-04:00,MNOV,positive
837264.0,Morning Market Gainers,2015-04-16 09:44:00-04:00,MNOV,neutral
837265.0,MediciNova Announces FDA Fast Track Designation for MN-001 for Treatment of NASH with Fibrosis,2015-04-16 08:01:00-04:00,MNOV,neutral
837266.0,Morning Market Gainers,2015-02-17 09:43:00-05:00,MNOV,neutral
837267.0,MediciNova Reports 30 of 60 Planned Subjects Enrolled in Clinical Trial of MN-166 in ALS,2015-02-16 19:00:00-05:00,MNOV,neutral
837268.0,MediciNova Announces FDA Approval of Protocol for Phase 2 Trial of MN-001 in IPF,2015-02-10 08:02:00-05:00,MNOV,positive
837269.0,MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of NASH,2015-02-03 18:00:00-05:00,MNOV,neutral
837270.0,"MN-166 Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC",2015-02-01 19:11:00-05:00,MNOV,positive
837271.0,MediciNova Shares Rise 20% on Report of Filing for Patent for Treatment of Progressive Neurodegenerative Disease With Ibudilast,2015-01-08 14:53:00-05:00,MNOV,positive
837272.0,"From 10-Q Filing: MediciNova, Inc. Reports Q3 EPS of $(0.10), Up 29% YOY",2014-11-13 17:08:00-05:00,MNOV,neutral
837273.0,MediciNova Receives Feedback from FDA Regarding Study Protocol for Phase 2 Trial of MN-001 in NASH ,2014-10-08 22:05:00-04:00,MNOV,neutral
837274.0,MediciNova's Announces MN-001 NASH Abstract Selected for Late-Breaking Session at the 65th Annual AASLD Meeting in Boston ,2014-10-06 19:34:00-04:00,MNOV,neutral
837275.0,Overview of MediciNova's Clinical Trial of MN-166 in ALS to be Presented at 13th Annual NEALS Meeting ,2014-09-29 20:59:00-04:00,MNOV,neutral
837276.0,MediciNova Provides Update on Phase 2b Trial of MN-166 in Progressive MS ,2014-09-23 19:30:00-04:00,MNOV,neutral
837277.0,MediciNova Receives Patent for Method of Treating Non-alcoholic Fatty Liver Disease and Steatohepatitis (NASH),2014-09-16 09:46:00-04:00,MNOV,neutral
837278.0,Morning Market Movers ,2014-09-10 09:39:00-04:00,MNOV,neutral
837279.0,Benzinga's Top #PreMarket Gainers,2014-09-10 08:09:00-04:00,MNOV,positive
837280.0,MediciNova Announces $2.66M NIDA Grant for MN-166 in Opioid Dependence ,2014-09-07 19:19:00-04:00,MNOV,positive
837281.0,US Stock Futures Surge Ahead Of Economic Data,2014-08-26 07:36:00-04:00,MNOV,neutral
837282.0,MediciNova to Initiate Clinical Trial of MN-166 in ALS ,2014-08-26 05:34:00-04:00,MNOV,neutral
837283.0,Morning Market Movers ,2014-08-19 09:40:00-04:00,MNOV,neutral
837284.0,"MediciNova Receives Notice of Allowance for New Patent Covering MN-001, MN-002 for Treatment of NAFLD",2014-08-11 19:15:00-04:00,MNOV,neutral
837285.0,"Medicinova Reports Positive Results of MN-001 in Advanced NASH Mouse Model, Requests Meeting with FDA",2014-08-05 07:50:00-04:00,MNOV,positive
837286.0,MediciNova Announces Positive Results Of MN-001 In Advanced NASH Mouse Model; MediciNova Requests A Meeting With FDA,2014-08-05 07:42:00-04:00,MNOV,positive
837287.0,MediciNova Announces Positive Results From Second Preclinical Study,2014-08-05 07:33:00-04:00,MNOV,positive
837288.0,MediciNova Announces Positive Results in Study of MN-001 in Mouse Model of Pulmonary Fibrosis ,2014-06-11 22:51:00-04:00,MNOV,positive
837289.0,MediciNova Sees FY2014 EPS $(0.38),2014-03-28 06:25:00-04:00,MNOV,neutral
837290.0,Benzinga's Top #PreMarket Losers,2014-01-16 08:22:00-05:00,MNOV,negative
837291.0,Morning Market Movers ,2014-01-14 09:55:00-05:00,MNOV,neutral
837292.0,MediciNova Announces Positive Results in NASH Mouse Model With MN-001 and Prepares to Initiate Phase 2 Trial in the U.S.,2014-01-14 08:05:00-05:00,MNOV,positive
837293.0,Medicinova Announces $6M Milestone Payment from Genzyme for Therapy for Parkinson's,2014-01-13 17:21:00-05:00,MNOV,neutral
837294.0,Medicinova Names Geoffrey O'Brien as VP,2013-10-16 16:31:00-04:00,MNOV,neutral
837295.0,MediciNova Receives Notice of Allowance for Pending Patent Application Covering MN-029 ,2013-10-06 23:19:00-04:00,MNOV,neutral
837296.0,NIAAA Funds Clinical Trial of MediciNova's MN-166 in Treating Alcoholism ,2013-08-25 19:16:00-04:00,MNOV,neutral
837297.0,"MediciNova, Inc. Reports Q2 EPS of $(0.14) vs $(0.11) Est",2013-08-08 17:30:00-04:00,MNOV,neutral
837298.0,MediciNova Initiates Cooperative Phase 2b Trial of MN-166 in Progressive Multiple Sclerosis ,2013-07-18 19:26:00-04:00,MNOV,neutral
837299.0,Morning Market Movers ,2013-06-19 09:59:00-04:00,MNOV,neutral
837300.0,Morning Market Movers,2013-05-13 10:02:00-04:00,MNOV,neutral
837301.0,"MediciNova, Inc. Reports Q1 EPS of $(0.14) vs $(0.13) Est",2013-05-08 17:32:00-04:00,MNOV,neutral
837302.0,Benzinga's Small Cap Movers for Tuesday February 26 2013,2013-02-26 20:35:00-05:00,MNOV,neutral
837303.0,FDA Grants Fast Track Designation for MediciNova's MN-166 for the Treatment of Methamphetamine Dependence,2013-02-25 18:02:00-05:00,MNOV,positive
837304.0,MediciNova Provides Development Update on MN-221 and MN-166,2013-01-03 19:18:00-05:00,MNOV,neutral
837305.0,MediciNova Receives Notice of Patent Allowance for MN-221 for Treatment of Acute Exacerbations of Asthma,2012-12-09 19:27:00-05:00,MNOV,neutral
837306.0,MediciNova Initiates Clinical Trial of MN-166 in Opioid Abusers ,2012-11-20 21:50:00-05:00,MNOV,negative
837307.0,MediciNova Receives Notices of Allowance from European Patent Office,2012-11-18 18:25:00-05:00,MNOV,neutral
837308.0,Medicinova Says Positive Phase 2 Results in 2 Asthma Studies,2012-11-12 18:03:00-05:00,MNOV,positive
837309.0,"MediciNova Says Considering Cost, Timing and Design of Future Trials; FDA Said Cut in Hospitalizations Should be Endpoint",2012-11-08 18:03:00-05:00,MNOV,negative
837310.0,MediciNova Receives Notice of European Patent Allowance for Treating Progressive MS,2012-10-25 19:06:00-04:00,MNOV,neutral
837311.0,MediciNova Met With FDA Monday for End-of-Phase 2  for MN-221 for the Treatment of Acute Exacerbations of Asthma ,2012-10-22 20:12:00-04:00,MNOV,neutral
837312.0,NIH Funds UCLA Phase 2 Study of MediciNova's MN-166 in Treating Drug Addiction ,2012-09-04 20:37:00-04:00,MNOV,neutral
837313.0,McNicoll Lewis Vlak Terminates Coverage on Medicinova,2012-08-27 05:55:00-04:00,MNOV,neutral
837314.0,"MediciNova Announces Positive Preliminary Results From a Multi-Day, Repeat-Dose Clinical Trial With MN-221 in Chronic Obstructive Pulmonary Disease Patients ",2012-08-23 20:08:00-04:00,MNOV,positive
837315.0,"Benzinga's Microcap Movers for Tuesday July 3, 2012",2012-07-04 13:58:00-04:00,MNOV,neutral
837316.0,MediciNova Pops 23% on Upcoming Meeting with FDA,2012-07-03 10:16:00-04:00,MNOV,neutral
837317.0,Morning Market Movers,2012-07-03 09:46:00-04:00,MNOV,neutral
837318.0,From Earlier: MediciNova Announces Scheduling of End-of-Phase 2 Meeting With FDA for MN-221 for the Treatment of Acute Exacerbations of Asthma  ,2012-07-03 07:07:00-04:00,MNOV,neutral
837319.0,"UPDATE: Rodman & Renshaw Places PT on MediciNova Under Review, Maintains Outperform",2012-06-19 08:17:00-04:00,MNOV,neutral
837320.0,Medicinova Resumes Trading,2012-05-23 16:31:00-04:00,MNOV,neutral
837321.0,MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma Exacerbations; Company Intends to Move Forward With End-of-Phase 2 Meeting With FDA and Phase 3 Clinical Development ,2012-05-23 16:00:00-04:00,MNOV,neutral
837322.0,From Earlier: MediciNova Receives Notice of an Australian Patent Allowance for a Method of Treating Neuropathic Pain  ,2012-04-24 07:28:00-04:00,MNOV,negative
837324.0,From Earlier: MediciNova Completes Enrollment in Phase 2 MN-221 Trial Treating Patients Suffering from Acute Exacerbations of Asthma  ,2012-03-22 06:52:00-04:00,MNOV,negative
837325.0,From Earlier: MediciNova Receives Notice of a Japanese Patent Allowance for a Method of Treating Neuropathic Pain  ,2012-03-14 06:52:00-04:00,MNOV,negative
837326.0,"Benzinga's Microcap Movers for Thursday February 2, 2012",2012-02-02 21:04:00-05:00,MNOV,neutral
837327.0,Mid-Day Market Movers,2012-02-02 12:21:00-05:00,MNOV,neutral
837328.0,MediciNova to Receive $2.5 Million Payment From Kissei Pharmaceutical Co. Ltd. to Expand Clinical Development of the MN-221 Program ,2011-10-14 06:57:00-04:00,MNOV,positive
837329.0,MediciNova Announces Private Sale of Stock to Kissei Pharmaceutical Co.,2011-09-27 06:48:00-04:00,MNOV,neutral
837330.0,"MediciNova Announces CFO, CMO Appointments",2011-09-02 06:58:00-04:00,MNOV,neutral
837331.0,Earnings Scheduled For August 16,2011-08-16 04:19:00-04:00,MNOV,neutral
837332.0,Global Hunter Initiates Coverage of MediciNova with Speculative Buy and PT of $4,2011-06-22 09:55:00-04:00,MNOV,positive
837333.0,"Global Hunter Initiates MediciNova At Buy, $4 PT",2011-06-22 07:36:00-04:00,MNOV,neutral
837334.0,"Earnings Scheduled For May 16 (VOXX, JCP, ALN, LOW, STV, WINN, SORL, GLPW, CTRP, URBN, JST, ZOOM, DL, MNOV, DRJ, JADE, FMD, CTC, GLGL, CHGS, GOK, GSL)",2011-05-16 00:48:00-04:00,MNOV,negative
837335.0,"Morning Market Losers (MNOV, IRDMW, PCE, SCHL)",2011-03-24 09:53:00-04:00,MNOV,negative
837336.0,"Benzinga's Top Pre-Market NASDAQ Losers (MNOV, SPU, IRDM, JRCC)",2011-03-24 08:13:00-04:00,MNOV,negative
837337.0,MediciNova Announces Proposed Public Offering of Common Stock and Warrants  ,2011-03-23 16:16:00-04:00,MNOV,neutral
837338.0,"Biotech/Pharma Stocks News; Joint Venture - MediciNova, Inc (Nasdaq:MNOV) and Zhejiang Medicine Co., Ltd. to Partner in China",2011-03-04 08:00:00-05:00,MNOV,neutral
837339.0,"Biotech/Pharma Stocks News; Joint Venture - MediciNova, Inc (Nasdaq:MNOV) and Zhejiang Medicine Co., Ltd. to Partner in China",2011-03-04 08:00:00-05:00,MNOV,neutral
837340.0,MediciNova Announces Joint Venture,2011-03-03 16:31:00-05:00,MNOV,neutral
837341.0,$5 Stocks That Analysts Expect to Double,2010-08-03 07:35:00-04:00,MNOV,neutral
